This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Elsevier Announces A New Concept Methods Journal: MethodsX

AMSTERDAM, February 3, 2014 /PRNewswire/ --

Open Access journal MethodsX provides a home for publishing work which otherwise remains unpublished

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced a new concept methods journal: MethodsX.

Researchers spend up to 80% of their time customizing and tweaking existing methods to make them better fit their specific research setting. By providing a home for these often unpublished records, MethodsX allows researchers to receive public credit and citations for that work without spending time writing a full, traditional research article.

"This is a new approach to scientific publishing. We believe that MethodsX will dramatically change how researchers assess and build on recognized techniques, saving the scientific community valuable time and money," commented Irene Kanter-Schlifke, Executive Publisher at Elsevier.

As an online-only, open access journal, MethodsX publishes papers in all disciplines of experimental research, from Life Sciences to Health Sciences to Physical Sciences.

A paper published in MethodsX includes:

  • an abstract to outline the customization
  • an image, graph or other visual to illustrate what's been done
  • the methodological protocol(s)

" MethodsX fulfills a real need for researchers to publish their work on developing methods so that they can easily be found by others," said Gregory J. Tsongalis, Advising Editor for MethodsX and Professor of Pathology at the Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth. "It's also good for researchers as they can get recognized for their time and effort."

The first articles are now freely available online on ScienceDirect: http://www.sciencedirect.com/science/article/pii/S2215016114000028

For more information or to submit an article, visit http://www.elsevier.com/locate/methodsx

# # #

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,132.70 -81.72 -0.45%
S&P 500 2,104.50 -6.24 -0.30%
NASDAQ 4,963.5270 -24.3630 -0.49%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs